ArticleBMC cancer2024

Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.

Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.